Facts
- HQ
- Seattle area
- Sectors
- Biotechnology Research
- Founded
- 2023
- Type
- Corporation Seattle business license
- Employees
- 10
- Registered name
- Lila Biologics Inc Seattle business license
- Total raised
- $9.5M SEC Form D filings Total of this company's SEC Form D filings
- Last round
- $9.5M · Sep 2023 SEC Form D
- Founders
- Jake Kraft, PhD, Anindya Roy, PhD, Hua Bai, PhD, Sheila Gujrathi, MD
GeekWire and Greater Seattle Partners call for nominations for 2026 Uncommon Thinkers; deadline Sept. 18, winners honored Dec. 10
Nominations for GeekWire’s 2026 Uncommon Thinkers Awards — honoring Seattle-area inventors, scientists, technologists and entrepreneurs — close Friday, Sept. 18 at 11 a.m. PT; winners will be chosen by a judges panel and celebrated at the GeekWire Gala on Dec. 10. The fourth annual program, run with Greater Seattle Partners, seeks nominees who demonstrate innovation, leadership and measurable impact.
GeekWire Honors Six 'Uncommon Thinkers' Transforming Industries with Innovative Startups in 2025
GeekWire's third annual 'Uncommon Thinkers' honors six innovators including Anindya Roy, Kiana Ehsani, and Jeff Thornburg, who are leading startups transforming industries with breakthrough technologies in biotech, social media, and space propulsion. These leaders will be celebrated at the GeekWire Gala in Seattle for their creative and mission-driven approaches to solving significant challenges.
Anindya Roy Co-founds Lila Biologics to Advance AI-Driven Medical Therapies After Journey from Rural India to UW Lab
Anindya Roy, who moved from rural India to the U.S. in 2008 with limited resources, has co-founded Lila Biologics in 2023 to develop innovative medical therapies using AI-powered protein design. His journey from humble beginnings to a postdoctoral fellowship under Nobel laureate David Baker exemplifies determination and scientific innovation.
Fred Hutch-Led Synthesize Bio Raises $10M to Accelerate Drug Discovery Using AI Gene Expression Model
Seattle-based Synthesize Bio, led by Fred Hutchinson Cancer Center researchers, raised $10 million from Madrona to accelerate drug discovery using their AI model GEM-1, which predicts gene expression outcomes with lab-level accuracy. The startup aims to reduce drug development time and costs by simulating hypothetical lab experiments with generative genomics.
Lila Biologics, Nobel Laureate’s Startup, Partners with Eli Lilly to Develop AI-Based Tumor Therapies
Lila Biologics, a startup from Nobel Laureate David Baker's University of Washington lab, is collaborating with Eli Lilly to develop AI-powered tumor-targeted therapies, aiming to deliver a candidate protein for clinical trials within six months. The startup utilizes AI and machine learning platforms to create therapeutic proteins for targeted radiotherapy and long-acting injectable drugs.
People
-
Anindya Roy Founder, Co-founder, Executive Officer, Director
-
Jake Kraft Executive, CEO
